Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
Zimbabwe is one of the world's first countries to roll out lenacapavir, a long-acting HIV prevention drug that is ...
Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Today we're going ...
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda. A multi-national, ...
Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the ...
Major trial finds immediate or high-dose TB treatment does not lower overall mortality in HIV-related sepsis, except in ...
Observers are calling proposed changes to state-funded HIV assistance its biggest rollback since the aid went into place.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results